Technical Analysis for RNUGF - Reneuron Group Plc

Grade Last Price % Change Price Change
grade B 2.52 6.78% 0.1600
RNUGF closed up 6.78 percent on Friday, August 16, 2019, on 16 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical RNUGF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 6.78%
Stochastic Reached Oversold Weakness 6.78%
Wide Bands Range Expansion 6.78%
Below Lower BB Weakness 6.78%
Gapped Down Weakness 6.78%
Oversold Stochastic Weakness 6.78%

Older signals for RNUGF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Medicine RTT Emerging Technologies Stem Cells Cell Therapy Ophthalmology Vision Stem Cell Therapy Stroke Blindness Retina Channelopathies Retinitis Pigmentosa
Is RNUGF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.43
52 Week Low 0.017
Average Volume 2,480
200-Day Moving Average 0.0
50-Day Moving Average 2.7999
20-Day Moving Average 2.898
10-Day Moving Average 2.821
Average True Range 0.2346
ADX 20.08
+DI 32.6026
-DI 52.1709
Chandelier Exit (Long, 3 ATRs ) 3.0462
Chandelier Exit (Short, 3 ATRs ) 3.0638
Upper Bollinger Band 3.4512
Lower Bollinger Band 2.3448
Percent B (%b) 0.16
BandWidth 38.178054
MACD Line -0.0965
MACD Signal Line 0.0038
MACD Histogram -0.1003
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.5200
Resistance 3 (R3) 2.5200 2.5200 2.5200
Resistance 2 (R2) 2.5200 2.5200 2.5200 2.5200
Resistance 1 (R1) 2.5200 2.5200 2.5200 2.5200 2.5200
Pivot Point 2.5200 2.5200 2.5200 2.5200 2.5200
Support 1 (S1) 2.5200 2.5200 2.5200 2.5200 2.5200
Support 2 (S2) 2.5200 2.5200 2.5200 2.5200
Support 3 (S3) 2.5200 2.5200 2.5200
Support 4 (S4) 2.5200